It's called myasthenia gravis and affects only about 37 out of every 100,000 people in the United States. Despite being so rare, "improved awareness and diagnostic techniques have led to more ...

While myasthenia gravis is a chronic condition that doesn ... and is approved for people who have tested positive for anti-acetylcholine receptor antibodies. Taking eculizumab may increase ...

Across 5 research centers, investigators evaluated the impact of eculizumab on thymoma-associated myasthenia gravis, a severe ...

The FDA has granted priority review to a Biologics License Application for nipocalimab to treat individuals with generalized ...

According to the Myasthenia Gravis Foundation of America (MGFA), 1 in 10 people with MG experience slurred speech and 2 in 100 people develop a voice disorder. Learn more about the benefits of ...

The prevalence and incidence rates of myasthenia gravis in the elderly US population have increased from 2006 to 2019.

The application is supported by data from the randomized, double-blind, placebo-controlled phase 3 Vivacity-MG3 study.

Patients with generalized myasthenia gravis experienced durable improvements across measures of efficacy and regardless of the time since they were diagnosed.